Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$482.13M+30.12%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Uwe Ferdinand Röhrhoff
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 13,528
- Beta
- 0.47
- Country
- DE
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 0.85
Financials
Revenue
$482.13M+30.1%Net Income
$-99.81M-439.8%EBITDA
$9.70M-88.1%Free Cash Flow
$-40.62M-355.4%EPS (diluted)
$-2.89-407.4%Shares Outstanding (diluted)
34.54M+10.5%Operating Expenses
$97.05MCash & Debt
$167.97MReturn of Capital
$0.00Dividend per Share
$0.05Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.32B | $-320.32M | $-9.27 |
| 2024 | $2.04B | $109.72M | $3.18 |
| 2023 | $1.99B | $116.13M | $3.48 |
| 2022 | $1.82B | $96.12M | $3.06 |
| 2021 | $1.50B | $83.79M | $2.67 |
| 2020 | $1.42B | $88.56M | $2.82 |
| 2019 | $1.39B | $80.78M | $2.57 |
| 2018 | $1.37B | $128.97M | $4.11 |
| 2017 | $1.35B | $100.89M | $3.21 |
| 2016 | $1.38B | $121.64M | $3.87 |
| 2015 | $1.38B | $104.22M | $3.32 |
| 2014 | $1.29B | $66.34M | $2.11 |
| 2013 | $1.27B | $62.16M | $1.98 |
| 2012 | $1.22B | $62.02M | $1.98 |
Valuation
GRRMFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
147+633.33%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·11d ago·Positive
Gerresheimer AG (GRRMY) Q2 2026 Earnings Call Transcript Gerresheimer AG (GRRMY) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·11d ago·Neutral
What Gerresheimer (GXI) Said on Its Q2 Earnings Call Gerresheimer ETR: GXI reported a sequential improvement in preliminary second-quarter 2026 results, with adjusted EBITDA rising more than 50% from the first quarter as operational initiatives began to contribute across all three business segments.
View source ↗ - Newsreuters.com·11d ago·Negative
Gerresheimer reports lower half-year core profit Drug-packaging maker Gerresheimer reported a lower core profit for the first half of 2026 on Wednesday, as weakness in its Moulded Glass business and lower demand for injection vials weighed on performance.
View source ↗ - Newsmarketbeat.com·45d ago·Negative
Gerresheimer Q1 Earnings Call Highlights Gerresheimer ETR: GXI reported preliminary first-quarter 2026 results that showed modest revenue growth but lower earnings as the packaging and drug-delivery company prioritized cash preservation, reduced capital spending and limited inventory buildup.
View source ↗
Earnings
Wed, Nov 4(in 3 weeks)
Consensus estimate $0.29 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 28$-0.27 vs $-0.14miss
- Tue, Mar 31$0.38 vs $0.38beat
- Wed, Feb 25$-0.07 vs $-0.07beat
- Fri, Oct 10$0.81 vs $0.95miss
- Thu, Jul 10$1.02 vs $0.92beat
- Fri, Apr 11$0.48 vs $0.25beat
Estimates and results for GRRMF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in GRRMF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.